SEREX: A promising approach for identification of thyroid cancer serological biomarkers

Clinical Endocrinology

Volumn 79, Issue 1, 2013, Pages 12-13

  Vitale, Mario ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CANCER ANTIBODY; TUMOR MARKER;

ADVANCED CANCER; ANTIBODY LIBRARY; CANCER SCREENING; COST; HUMAN; NOTE; PRIORITY JOURNAL; SEROLOGY; THYROID CANCER; THYROID MEDULLARY CARCINOMA;

ANTIGENS, NEOPLASM; GENE LIBRARY; HUMANS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878529104     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12161     Document Type: Note

References (16)

1. Gharib, H., &, Goellner, J.R., (1993) Fine-needle aspiration biopsy of the thyroid: an appraisal. Annals of Internal Medicine, 118, 282-289.
2. Sapio, M.R., Guerra, A., Posca, D., et al,. (2007) Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocrine-Related Cancer, 14, 1089-1097.
3. Guerra, A., Sapio, M.R., Marotta, V., et al,. (2011) Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocrine Journal, 58, 31-38.
4. Guerra, A., Fugazzola, L., Marotta, V., et al,. (2012) A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. Journal of Clinical Endocrinology and Metabolism, 97, 2333-2340.
5. Sahin, U., Tureci, O., Schmitt, H., et al,. (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proceedings of the National Academy of Sciences of the United States of America, 92, 11810-11813.
6. Zhong, L., Ge, K., Zu, J.C., et al,. (2008) Autoantibodies as potential biomarkers for breast cancer. Breast Cancer Research, 10, R40.
7. Chang, W., Wu, L., Cao, F., et al,. (2011) Development of autoantibody signatures as biomarkers for early detection of colorectal carcinoma. Clinical Cancer Research, 17, 5715-5724.
8. Maio, M., Coral, S., Sigalotti, L., et al,. (2003) Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. Journal of Clinical Endocrinology and Metabolism, 88, 748-754.
9. Kiyamova, R., Garifulin, O., Gryshkova, V., et al,. (2012) Preliminary study of thyroid and colon cancers-associated antigens and their cognate autoantibodies as potential cancer biomarkers. Biomarkers, 17, 362-371.
10. Izawa, S., Okamura, T., Matsuzawa, K., et al,. (in press) Autoantibody against WD repeat domain 1 is a novel serological biomarker for screening of thyroid neoplasm. Clinical Endocrinology (Oxford), 79, 35-42.
11. Nucera, C., Lawler, J., &, Parangi, S., (2011) BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Research, 71, 2417-2422.
12. Vitale, M., Bassi, V., Illario, M., et al,. (1994) Loss of polarity and de novo expression of the beta 1 family of integrins in thyroid tumors. International Journal of Cancer, 59, 185-190.
13. Di Matola, T., Mueller, F., Fenzi, G., et al,. (2000) Serum withdrawal-induced apoptosis in thyroid cells is caused by loss of fibronectin-integrin interaction. Journal of Clinical Endocrinology and Metabolism, 85, 1188-1193.
14. Nucera, C., Lawler, J., Hodin, R., et al,. (2010) The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget, 1, 751-756.
15. Chen, Y.T., &, Old, L.J., (1999) Cancer-testis antigens: targets for cancer immunotherapy. The Cancer Journal from Scientific American, 5, 16-17.
16. Banchereau, J., &, Steinman, R.M., (1998) Dendritic cells and the control of immunity. Nature, 392, 245-252.